Trials / Completed
CompletedNCT00429559
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Weekly Administration of Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Hellenic Oncology Research Group · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administered weekly in patients with platinum -resistant ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hycamptin | 1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression |
| DRUG | Gemcitabine | Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks. Number of cycles: until progression |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2007-01-31
- Last updated
- 2011-07-22
Locations
6 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00429559. Inclusion in this directory is not an endorsement.